Sports
Press Release: Tolebrutinib Designated Breakthrough Therapy By The FDA For Non-Relapsing Secondary Progressive Multiple Sclerosis
(MENAFN - GlobeNewsWire - Nasdaq) Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from ...
By: menafn
- Dec 13 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS